Bionano Laboratories announced the launch of OGM-Dx HemeOne, a laboratory developed test based on optical genome mapping analysis of blood or bone marrow samples to detect structural variants of diagnostic and prognostic utility in individuals with a new or an existing diagnosis of a hematological malignancy. Compared to traditional cytogenetic methods, this OGM-based assay offers a streamlined and improved workflow to assess pathogenic SVs relevant to hematological malignancies including Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia and Myelodysplastic Syndrome.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BNGO:
- Bionano Genomics announces launch of multiple new products
- Bionano Announces Launch of Next-Generation Versions of its Reagent Kits and Chip Consumable, Along with Updates to its Instrument Control and Bionano Access Software for the Optical Genome Mapping Workflow
- Bionano Genomics Announces the Final Speaker Lineup for Symposium 2023 with 30 OGM Presentations and Live Panel Discussions Across a Wide Range of Genetic Disease and Cancer Research Applications
- Bionano Genomics announces speaker lineup for Symposium 2023
- Bionano Genomics announces publication of interim readout from OGM trial